Applying the Evidence for GLP-1 Receptor Agonists in Type 2 Diabetes: Practice Perspectives

March 6, 2015

In this educational activity, 4 renowned experts in the treatment of type 2 diabetes mellitus (T2DM) will explore some of the unanswered questions about the GLP-1 RA drug class, and will discuss how these agents—especially newer formulations—fit into the updated T2DM treatment paradigm. Safety issues, tailoring therapy to the needs of each patient, and identifying and addressing potential clinical barriers will also be discussed.

Target Audience

This continuing medical education activity should be of substantial interest to endocrinologists, internists, and other health care professionals who treat patients with type 2 diabetes mellitus (T2DM).

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  • Evaluate the most recent evidence when considering use of a GLP-1 RA as part of a T2DM treatment plan
  • Review updated safety data for the GLP-1 RA drug class
  • Discuss the nonglycemic effects of GLP-1 RAs, including their positive impact on weight and cardiovascular risk factors
  • Describe the optimal use of GLP-1 RAs in the context of practice-based clinical scenarios

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Topic Area: 
Diabetes and Glucose Metabolism
Quality Improvement and Healthcare Delivery
General Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Activity summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credits
  • 2.00 CME Certificate of Participation
Course opens: 
Course expires: 
Event starts: 
03/06/2015 - 5:45am
Event ends: 
03/06/2015 - 8:00am
Hilton San Diego Bayfront
1 Park Boulevard
Sapphire Ballroom B
San Diego, CA
United States

Silvio E. Inzucchi, MD
Professor of Medicine
Clinical Director, Section of Endocrinology
Medical Director, Yale Diabetes Center
Yale School of Medicine
New Haven, CT

Sam Dagogo-Jack, MD, MBBS, FRCP
A.C. Mullins Chair in Translational Research
Professor of Medicine & Director
Division of Endocrinology, Diabetes & Metabolism
Director, Clinical Research Center
The University of Tennessee Health Science Center
Memphis, TN

Anne L. Peters, MD
Director, USC Clinical Diabetes Program
Professor, Keck School of Medicine of USC
Los Angeles, CA

Adrian Vella, MD
Professor of Medicine
Division of Endocrinology
Mayo Clinic & Foundation
Rochester, MN

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationships:
Silvio E. Inzucchi, MD: Research Support, Takeda; Scientific Board Member, Boehringer Ingelheim, Eisai, Lexicon Pharmaceuticals, Inc.; Speaker, AstraZeneca
Sam Dagogo-Jack, MD, MBBS, FRCP: Consultant, Merck & Co., Novo Nordisk; Principal Investigator, AstraZeneca, Boehringer Ingelheim, Novo Nordisk
Anne L. Peters, MD: Advisory Board Member, Abbott Lab, Amgen, AstraZeneca, Eli Lilly & Co., Janssen Pharmaceuticals, Lexicon Pharmaceuticals, Inc., Medtronic, Minimed, Novo Nordisk, Sanofi, Takeda; Investigator, Medtronic, Minimed, Janssen Pharmaceuticals; Speaker, Bristol-Myers Squibb, Novo Nordisk
Adrian Vella, MD: Consultant, Genentech, Inc., Sanofi; Research Funding,  BioKier, Novartis

The following SPC member who planned and/or reviewed content for this activity reported relevant financial relationships:
Anton Luger, MD: Advisory Board Member, Investigator, and Speaker, Novo Nordisk; Advisory Board Member and Speaker, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Ipsen, Merck, Merck, Novartis, Pfizer, Reckitt Benkiser, Sharp & Dome, Takeda; Investigator, Roche

The following SPC Committee members reported relevant financial relationships:
Sarah Berga, MD: Advisory Board Member, Agile Therapeutics, Noven Pharmaceuticals, Inc., Watson Pharmaceuticals, Teva Pharmaceuticals Industries, Shionogi, Inc.; Consultant, AHC Media, LLC, Shionogi, Inc.
Paresh Dandona, MD, PhD, FRCP: Consultant and Speaker, AstraZeneca, Bristol Myers Squibb, Janssen, Novo Nordisk
Irl B. Hirsch, MD: Consultant: Abbott Laboratories, Becton Dickinson, Roche Diagnostics; Grant Support, Halozyme, Sanofi
E. Michael Lewiecki, MD: Consultant, Amgen, Eli Lilly, Merck, Radius Health, AgNovos Healthcare, Theranova; Research Grant Support, Amgen, Eli Lilly, Merck
Lisa Nachtigall, MD: Consultant, Genentech; Consultant and Principal Investigator, Ipsen
Amy Rothberg, MD: Consultant, Novo Nordisk; Speaker, Takeda Pharmaceuticals
Guillermo E Umpierrez, MD, CDE: Advisory Board and Consultant, Abbott, Boehringer Ingelheim, Merck, Novo Nordisk, Regeneron, Sanofi; Research Grant Support, Boehringer Ingelheim, Merck, Novo Nordisk, Regeneron
Andrea L Utz, MD, PhD: Investigator, Corcept, Ipsen

The following SPC members reported no relevant financial relationships: Jeffrey Boord, MD, MPH; Larry Fox, MD; Michael S Irwig, MD; Connie B Newman, MD

Endocrine Society and Haymarket Medical Education staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 2.00 AMA PRA Category 1 Credits
  • 2.00 CME Certificate of Participation